Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and... see more

TSX:ONC - Post Discussion

Oncolytics Biotech Inc > Latest news very good
View:
Post by canadafan on Feb 15, 2024 12:32pm

Latest news very good

The most recent newsprogressing with another phase if the Gobblet trial co- therapy with Roche can only be viewed as good news. Ideally Roche steps up & buys the whole company. It was always noted by management, Majority of acquisitions came on the results of long standing clinical relationships. They certainly have that with Roche. Not to mention the phase 3 fast track approval for the pancreatic cancer co therapy.
Comment by JohnnyYeg on Feb 15, 2024 1:29pm
AND the FDA has accepted the sBLA (supplemental Biologics Application) and assigned a PDUFA (Prescription Drug User Fee Act) goal date of October 8, 2024
Comment by Noteable on Feb 15, 2024 2:05pm
The FDA assigning ONCY a PDUFA date for a supplemental Biologics Application (sBLA) is fake - and doesn't appear on any FDA calendars. This is because ONCY currently does not have any approved products for a "supplementary" BLA to be filed against.  https://www.benzinga.com/fda-calendar?date_from=2024-10-01&date_to=2024-10-19&securities=ONCY  ...more  
Comment by Noteable on Feb 15, 2024 2:18pm
" Supplement - A request to FDA to approve a change to an approved license application." FDA Standard Operating Policy and Procedure (SOPP) guideline - SOPP 8401.2: Administrative Processing of BLA and NDA Supplements Version: 10 Effective Date: February 8, 2024 https://www.fda.gov/media/108895/download
Comment by JohnnyYeg on Feb 15, 2024 2:28pm
Correct Noteable - my bad. It was a misleading link header that used the ONCY ticker symbol and the FDA PDUFA details when in fact the PDUFA mentioned in the article was for Bristol Myers Squibb's section in the article. My apologies folks.
Comment by lonc17 on Feb 15, 2024 2:14pm
A buyout by Roche could happen anytime. It needs to happen very soon otherwise ONC is facing a capital raise that will decimate existing shareholders. No one "invests" by buying shares in ONC at this time. It is a pure speculative gamble with a timeframe of less than two months. Roche buyout... you win at least 10x Dilutive financing ... you lose half your money, likely never to see ...more  
Comment by lonc17 on Feb 15, 2024 3:19pm
Really if you are doing and expected value calculatoin then you may consdier the possiblility of 20x (or even 30x if bidding war ensues). But MC would need a team of expert negotiators to pull that off. 
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities